A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)

Trial Profile

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs V 212 (Primary)
  • Indications Herpes zoster
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 08 Oct 2017 Results of exploratory analysis assessing immunogenicity of the varicella zoster virus vaccine V 212 in autologous hematopoietic cell transplant recipients for the prevention of herpes zoster, were presented at the IDWeek 2017.
    • 04 Oct 2017 According to a Merck & Co media release, new data analysis from the study will be presented at ID Week 2017.
    • 24 Feb 2017 Primary endpoint (Incidence of herpes zoster (HZ)) has been met, according to a Merck & Co media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top